Welcome to the Abel Lab!

Care Delivery Research for Patients with Blood Cancers 

The Abel Lab at Dana-Farber Cancer Institute applies health services research methods to understand the experiences of patients with blood cancers and develop interventions to improve care.

We are interested in evaluating how cancer and its therapies affect outcomes such as function and quality of life. Through our work and collaboration with researchers in oncology, hematology, geriatrics, ethics, and energy balance, we aim to ameliorate the impact of hematologic malignancies and their treatment from diagnosis to the end of life.

Dr. Abel discusses the care delivery and bioethics impact of telemedicine implementation at Dana-Farber with Dr. Wagner, the Medical Director of Adult Ambulatory Oncology.

Explore this website to learn about the Abel Lab’s current research and former projects.

• The largest study from the OHM project, entitled "Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers," was published in Haematologica.

   

• The MDS Natural History Study paper, "Clinical and genomic convergence of high-risk CCUS and lower-risk myelodysplastic syndromes/neoplasms," was published in Blood.

   

• The Abel Lab will be presenting several abstracts at the 2026 ASCO Quality Care Symposium in October, including "Content validity of overtreatment and undertreatment in older adults with cancer: A multi-stakeholder qualitative study of new definitions" with first author lab member Ameya Sanyal.

   

• Dr. Hantel's paper, "Ethical design and implementation of monetary transfer interventions in clinical cancer research," was published in the Journal of Clinical Oncology.